Thermo Fisher Scientific Inc. $TMO Shares Sold by Diversify Advisory Services LLC

Diversify Advisory Services LLC lowered its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 49.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,039 shares of the medical research company’s stock after selling 1,015 shares during the quarter. Diversify Advisory Services LLC’s holdings in Thermo Fisher Scientific were worth $643,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also made changes to their positions in the company. JPL Wealth Management LLC acquired a new stake in shares of Thermo Fisher Scientific during the third quarter worth approximately $28,000. Highline Wealth Partners LLC grew its position in shares of Thermo Fisher Scientific by 126.9% during the third quarter. Highline Wealth Partners LLC now owns 59 shares of the medical research company’s stock worth $29,000 after buying an additional 33 shares in the last quarter. Beacon Financial Strategies CORP acquired a new position in shares of Thermo Fisher Scientific in the 4th quarter worth approximately $29,000. Olistico Wealth LLC acquired a new position in shares of Thermo Fisher Scientific in the 4th quarter worth approximately $29,000. Finally, Cloud Capital Management LLC acquired a new position in shares of Thermo Fisher Scientific in the 3rd quarter worth approximately $31,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of the business’s stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $541.20, for a total value of $216,480.00. Following the transaction, the executive vice president owned 20,752 shares in the company, valued at $11,230,982.40. The trade was a 1.89% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Marc N. Casper sold 5,000 shares of the business’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $512.40, for a total value of $2,562,000.00. Following the completion of the transaction, the chief executive officer owned 123,925 shares in the company, valued at $63,499,170. This trade represents a 3.88% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Stock Up 2.5%

TMO opened at $527.26 on Wednesday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.53 and a current ratio of 1.89. The company has a market capitalization of $195.94 billion, a PE ratio of 29.72, a P/E/G ratio of 2.75 and a beta of 0.97. The stock’s fifty day moving average is $503.14 and its 200-day moving average is $550.25. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $643.99.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Thursday, January 29th. The medical research company reported $6.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.45 by $0.12. The business had revenue of $12.22 billion for the quarter, compared to analysts’ expectations of $11.95 billion. Thermo Fisher Scientific had a return on equity of 16.92% and a net margin of 15.05%.The company’s quarterly revenue was up 7.2% on a year-over-year basis. During the same period in the previous year, the firm posted $6.10 EPS. On average, equities analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 15th. Stockholders of record on Friday, March 13th will be issued a dividend of $0.47 per share. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date is Friday, March 13th. Thermo Fisher Scientific’s dividend payout ratio is presently 10.60%.

Wall Street Analyst Weigh In

Several brokerages have recently commented on TMO. Weiss Ratings reiterated a “hold (c)” rating on shares of Thermo Fisher Scientific in a research report on Wednesday, April 8th. TD Cowen decreased their target price on Thermo Fisher Scientific from $696.00 to $683.00 and set a “buy” rating for the company in a research report on Friday, January 30th. Wells Fargo & Company set a $683.00 target price on Thermo Fisher Scientific in a research report on Friday, January 30th. Barclays cut their price target on Thermo Fisher Scientific from $650.00 to $625.00 and set an “overweight” rating on the stock in a report on Tuesday. Finally, DZ Bank started coverage on Thermo Fisher Scientific in a research note on Friday, March 27th. They set a “buy” rating and a $610.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $631.25.

Key Thermo Fisher Scientific News

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Zacks and Yahoo analyses highlight Thermo Fisher as one of a small group of medical stocks likely to beat upcoming quarterly earnings (strong earnings-surprise history and favorable Earnings ESP), which can drive upside on an earnings beat. These 2 Medical Stocks Could Beat Earnings
• Positive Sentiment: Thermo Fisher’s PPD clinical research unit announced a strategic collaboration with HealthVerity to expand real‑world data capabilities — a revenue-accretive move that strengthens its clinical services offering and makes future contract wins more likely. Thermo Fisher PPD Clinical Research Collaborates with HealthVerity
• Positive Sentiment: Industry reports project strong growth in allergy diagnostics and small‑molecule CDMO markets through 2030–2033 and list Thermo Fisher as a leading participant — reinforcing a favorable long‑term demand outlook for its diagnostics and CDMO businesses. Allergy Diagnostic Market Forecast Small Molecule Innovator API CDMO Market Outlook
• Neutral Sentiment: Barclays cut its TMO price target from $650 to $625 but maintained an “Overweight” rating — a mild trimming of upside expectation but still institutional support for the stock. Barclays Lowers Price Target to $625
• Neutral Sentiment: Recent valuation commentary notes short‑term share volatility (mixed 1‑, 3‑month returns) — useful context for traders but not a direct fundamental change. Valuation and Volatility Analysis

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.